Phase 1 trial of ACT-017 for the treatment of Acute Ischemic Stroke
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs ACT 017 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- 05 Feb 2018 According to an Acticor Biotech media release, this study was conducted in the clinical research center of QPS (The Netherlands) and final report of the study is due in the coming weeks.
- 05 Feb 2018 Status changed from recruiting to completed, according to an Acticor Biotech media release.
- 17 Oct 2017 According to an Acticor Biotech media release, the results of this study are expected for Q1 2018, and will be used to determine the appropriate ACT017 dosage for phase II studies. The first cohort of volunteers will be enrolled by the end of October 2017.